UCB stock reaches EUR 278.95 after guidance upgrade

UCB stock was at EUR 278.95 at Lang & Schwarz on October 29, 2026, at 16:15:22 Berlin time. Compared with the EUR 268.00 quote recorded in our October 27 report, the price was 4.09 percent higher. This market comparison is separate from the company's operating update and does not by itself establish a causal price reaction.

On October 22, UCB announced a further upgrade to its 2026 financial guidance. In its official guidance release, the Belgian biopharmaceutical company said revenue growth should reach the low twenties at constant exchange rates, compared with the previous low-to-mid-teens range.

Higher growth, wider operating leverage

UCB also expects adjusted EBITDA growth in the low-to-mid-forties at constant exchange rates, up from the previous mid-teens to low-twenties range. The company said the higher revenue outlook should create significant operating leverage and margin expansion.

The upgrade was driven mainly by stronger BIMZELX performance in the United States. UCB cited robust patient demand, faster patient conversion, higher retention rates and more favorable net pricing linked to the channel mix. CIMZIA continued to deliver volume growth across markets despite a contracting anti-TNF market, while pricing trends improved.

The guidance excludes proceeds from the sale of a Priority Review Voucher. UCB said that transaction could provide an additional low-to-mid-single-digit percentage-point uplift to both revenue and adjusted EBITDA growth. Full-year 2026 results and formal 2027 guidance are scheduled for February 25, 2027.

What has changed since our last report

The operating news was already covered in prior reports, but the verified quote provides a fresh comparison point: the current Lang & Schwarz price is higher than the EUR 268.00 level recorded on October 27. Investors still need to distinguish the stronger guidance from valuation risk, execution requirements and the timing of future clinical and commercial developments.

For a live view, see the real-time quote of UCB stock.

Broader market developments can be followed in the Euro Stoxx 50 market context.

For more company developments, see More news and analyses on UCB stock.